POSC110 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 5-Year Pacific Data
Abstract
Authors
MJ Mooradian S Taylor R Ramsden M van Keep W Dunlop L Brannman C Yong